ERBB2 and breast cancer: Although the study sample size is small, the study showed favorable outcomes with a median OS of 17.9 months (95% CI 7.8-not reached) without any surgical intervention.812 In case of advanced/metastatic BC, the pan-ErbB inhibitor pyrotinib is being currently studied with trastuzumab, an anti-HER2 monoclonal antibody, and docetaxel as adjuvant-therapy in the phase 3 PHILA (NCT03863223); as neoadjuvant therapy in the PHEBA (NCT03588091) trial or with capecitabine in the phase 3 PHOEBE (NCT03080805) trial.813–815